In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...

Arrowhead Pharmaceuticals, Inc. today announced that it is scheduled to participate in the following upcoming events: Obesity KOL Webinar ? ARO-INHBE and ARO-ALK7 Interim Clinical Data ? January 6, ...

The Nasdaq-100 is reconstituted each year in December, timed to coincide with the quadruple witch expiration on the Friday of ...

Silence Therapeutics ( ($SLN) ) just unveiled an announcement. On December 18, 2025, Silence Therapeutics plc appointed its Executive Vice ...

The U.S. Environmental Protection Agency has approved the registration of Norroa, the first-ever RNA-based treatment for varroa mites, the leading threat to honeybee colonies. The new product from ...

< Photo 1. (From left) Professor Won Do Heo and Jihwan Yu, a Ph.D. Candidate of the Department of Biological Sciences > CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing ...

In April, the major pharma giants in the mergers and acquisitions (M&As) space were Novartis and Merck. Last month, however, the big names that announced multimillion-dollar buyouts were GSK, Sanofi, ...

Summary: Researchers have developed a new CRISPR-based technology that transports RNA to exact locations within neurons, where it can trigger repair and regrowth, offering hope for treating ...

When a neuron in our body gets damaged, segments of RNA produce proteins that can help repair the injury. But in neurological disorders such as ALS and spinal muscular atrophy, or following spinal ...